An Open-label, Single-arm Study to Assess the Safety Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis

Trial Profile

An Open-label, Single-arm Study to Assess the Safety Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2017

At a glance

  • Drugs Cinacalcet (Primary)
  • Indications Renal failure; Secondary hyperparathyroidism
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 22 Jun 2016 Status changed from active, no longer recruiting to discontinued.
    • 28 Apr 2016 Planned End Date changed from 1 Aug 2017 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top